Technology
Unlike traditional approaches, the Vanadis platform enables targeted cfDNA analysis without PCR by directly capturing and labeling target fragments from chromosomes 21, 18, 13, X & Y for counting. This eliminates the expensive, data-intensive steps typical of DNA sequencing and microarray-based technologies, making advanced testing more accessible.
The Vanadis platform simplifies complex cfDNA analysis while maintaining cutting-edge technology. It delivers cost-efficient results using standard microplates and fully automated processing-no genetic expertise required. With high molecular yield counting that minimizes failure rates, Vanadis is an optimized, accessible cfDNA platform for reliable analysis.
Workflow
Streamlined workflow from primary tube to final result
Analyze chromosomes 21, 18, 13, X and Y with Vanadis cfDNA platform. By targeting thousands of chromosomal sequences and counting an average of 650,000 molecules per chromosome, the Vanadis system delivers reliable cell-free DNA analysis for your laboratory.
Benefits
Why choose the Vanadis cfDNA platform?
The Vanadis cfDNA platform delivers a unique combination of simplicity and efficiency. Designed specifically for laboratories seeking reliable chromosomal analysis without the complexity of traditional sequencing methods.
The Vanadis cfDNA platform delivers a unique combination of simplicity and efficiency. Designed specifically for laboratories seeking reliable chromosomal analysis without the complexity of traditional sequencing methods.
Easy to use
Less hands-on time
Simplified reporting
Scalable throughput
Cost-effective
No hidden costs
Built to perform
Power in numbers
Minimize errors
Featured resource
References:
- Conotte S., El Kenz H., De Marchin J., Jani J.C. Cell-free DNA analysis for noninvasive examination of trisomy: comparing two targeted methods. American Journal of Obstetrics & Gynecology. 2022. doi: 10.1016/j.ajog.2022.05.024
- Pooh R.K. et al. Clinical Validation of Fetal cfDNA Analysis Using Rolling-CircleReplication and Imaging Technology in Osaka (CRITO Study). Diagnostics 2021, 11, 1837. doi: 10.3390/diagnostics11101837
